【摘要】 目的探讨环孢素A(CsA)联合造血生长因子治疗低危骨髓增生异常综合征(MDS)的临床疗效。方法用CsA联合造血生长因子治疗低危骨髓增生异常综合征患者30例,定期观察患者外周血象和骨髓象变化,并随诊观察远期疗效。结果30例患者治疗总有效率为80.0%(24/30)。70.0%(21/30)患者血液学指标改善并摆脱输血依赖,全部患者无严重毒副反应出现。结论CsA联合造血生长因子治疗低危骨髓增生异常综合征疗效可靠,耐受性好。更多还原

【Abstract】 Objective To explore the clinical result of cyclosporin A(CsA) combined with hematopoietic growth factor in the treatment of low-risk myelodysplastic syndrome(MDS).Methods 30 cases with low-risk MDS were treated with CsA and hematopoietic growth factor.The changes of peripheral blood cells and bone marrow were observed regularly.A follow-up observation for long-term therapy effect was carried out.Results The total effective rate of 30 patients was 80.0%(24/30).No serious side-effects occurred in all treated patients.The anemia in 70.0%(21/30) patients was improved and these transfusion-dependent patients achieved transfusion independence.Conclusions The treatment of low-risk MDS by CsA combined with hematopoietic growth factor is safe and effective.更多还原